Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Other Non-Current Assets (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Other Non-Current Assets for 3 consecutive years, with $461000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 72.66% to $461000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $461000.0, a 72.66% increase, with the full-year FY2025 number at $461000.0, up 72.66% from a year prior.
  • Other Non-Current Assets was $461000.0 for Q4 2025 at Artiva Biotherapeutics, up from $418000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $461000.0 in Q2 2025 to a low of $13000.0 in Q1 2025.
  • A 3-year average of $288000.0 and a median of $258000.0 in 2023 define the central range for Other Non-Current Assets.
  • Biggest YoY gain for Other Non-Current Assets was 78.68% in 2025; the steepest drop was 94.96% in 2025.
  • Artiva Biotherapeutics' Other Non-Current Assets stood at $258000.0 in 2023, then increased by 3.49% to $267000.0 in 2024, then surged by 72.66% to $461000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Other Non-Current Assets are $461000.0 (Q4 2025), $418000.0 (Q3 2025), and $461000.0 (Q2 2025).